^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Source:
Title:

Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma

Excerpt:
Similarly as AEB071 + CGM097, the AEB071 + MEK162 combination induced significant TGI in all five PDXs associated with combination activity in four models (Figure ​(Figure11 and Supplementary Figure S4)….Overall, our in vivo findings show that targeting of PKC and p53-MDM2 or PKC and mTORC1 are effective combination strategies for GNAQ/11 mutated UM PDXs, with tumor regressions often observed after PKC and p53-MDM2 inhibition.
DOI:
10.18632/oncotarget.9552